Targeting the translation machinery in cancer
The DOI matches its Crossref record; 291 of the 291 references it cites were found in a registry or an index.
Abstract
Dysregulation of mRNA translation is a frequent feature of neoplasia. Many oncogenes and tumour suppressors affect the translation machinery, making aberrant translation a widespread characteristic of tumour cells, independent of the genetic make-up of the cancer. Therefore, therapeutic agents that target components of the protein synthesis apparatus hold promise as novel anticancer drugs that can overcome intra-tumour heterogeneity. In this Review, we discuss the role of translation in cancer, with a particular focus on the eIF4F (eukaryotic translation initiation factor 4F) complex, and provide an overview of recent efforts aiming to 'translate' these results to the clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The natural product, silvestrol, and related compounds are selective and potent inhibitors of the RNA helicase and translation initiation factor eIF4A (Eukaryotic Translational Initiation Factor 4A, also known as DDX2) [20].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [20]
In the citing paper
“Our results build on studies in mouse models of other cancers, including lymphoma, leukemia, breast, prostate, and pancreatic cancer, supporting the tolerability and efficacy of eIF4A inhibitors (15, 17, 20, 21, 38).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [38]
In the citing paper
“Many direct eIF4A/eIF4F mRNA targets have been identified and often encode proteins that drive proliferation, metastasis, and survival (11, 14, 15).”
From Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer (2023) · cites this paper as [14]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Insights into the regulation of protein abundance from proteomic and transcriptomic analyses
Vogel, C., & Marcotte, E. M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3185 · Cited by 4,195
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Research works printed but not linked: 5
- Hershey, J. W. B., Sonenberg, N. & Mathews, M. in Protein Synthesis and Translational Control (eds Hershey, J. W. B. et al.) (Cold Spring Harbor Laboratory Press, 2012)
- Pianese, G. Beitrag zur histologie und aetiologie der carcinoma histologische und experimentelle. Beitr. Pathol. Anat. Allg. Pathol. 142, 1–193 (in German) (1896). First evidence that dysregulated translation has a major role in cancer by demonstrating that cancer cells have hypertrophic and irregularly shaped nucleoli.
- De Benedetti, A. et al. CHO cells transformed by the translation factor elF-4E display increased c-Myc expression, but require overexpression of Max for tumorigenicity. Mol. Cell. Diff. 2, 347–371 (1994).
- Ron, D. & Harding, H. in Translational Control in Biology and Medicine Ch. 13 (eds Matthews, M. B. et al.) (Cold Spring Harbor Laboratory Press, 2007).
- Bissler, J. J. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140–151 (2008). · DOI · Paper page
Cited by
Items 101–200 of 899
Active Ribosome Profiling with RiboLace
Clamer, M., Tebaldi, T., Lauria, F., Bernabò, P., Gómez-Biagi, R. F., Marchioretto, M., Kandala, D. T., Minati, L., Perenthaler, E., Gubert, D., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.09.084 · Cited by 87
A Quick Guide to Small-Molecule Inhibitors of Eukaryotic Protein Synthesis
Dmitriev, S. E., Vladimirov, D. O., & Lashkevich, K. A. (2020) · Biochemistry (Moscow) · doi:10.1134/s0006297920110097 · Cited by 90
Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth
Lee, B. J., Boyer, J. A., Burnett, G. L., Thottumkara, A. P., Tibrewal, N., Wilson, S. L., Hsieh, T., Marquez, A., Lorenzana, E. G., Evans, J. W., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00813-7 · Cited by 82
Self-citationeIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth
Strnádel, J., Choi, S., Fujimura, K., Wang, H., Zhang, W., Wyse, M. M., Wright, T., Gross, E. T. E., Peinado, C. D., Park, H. W., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2594 · Cited by 90
“Deregulation of protein synthesis is a hallmark of cancer characterized by hyperactive ribosome biogenesis and reprogramming of mRNA translation in a manner that favors proliferation, survival, and metastasis (1, 2).”
InfluentialNanoparticles for siRNA-Based Gene Silencing in Tumor Therapy
Babu, A., Muralidharan, R., Amreddy, N., Mehta, M., Munshi, A., & Ramesh, R. (2016) · IEEE Transactions on NanoBioscience · doi:10.1109/tnb.2016.2621730 · Cited by 88
“Over the past several years, researchers have made great achievements in elucidating cancer cell growth regulatory pathways and associated protein expressions leading to the identification of many druggable targets at the molecular level [2]–[5].”
BackgroundTahmasebi, S., Jafarnejad, S. M., Tam, I. S., Gonatopoulos-Pournatzis, T., Matta‐Camacho, E., Tsukumo, Y., Yanagiya, A., Li, W., Atlasi, Y., Caron, M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615540113 · Cited by 86
“encode proteins that control fundamental cellular processes such as cell proliferation and survival (16).”
BackgroundSelf-citationeIF4E-Dependent Translational Control: A Central Mechanism for Regulation of Pain Plasticity
Uttam, S., Wong, C., Price, T. J., & Khoutorsky, A. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00470 · Cited by 85
The multifaceted eukaryotic cap structure
Pelletier, J., Schmeing, T. M., & Sonenberg, N. (2020) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1636 · Cited by 84
“…been explored include suppression of eIF4E expression using antisense oligonucleotides and siRNAs, interfering with eIF4E-eIF4G interaction, blocking eIF4E:cap interaction, and inhibiting upstream mitogen-activated protein kinase (MAPK) signal-integrating kinases (MNK) 1 and 2 (Bhat et al., 2015).”
BackgroundSelf-citationTargeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates
Worm, D. J., Els‐Heindl, S., & Beck‐Sickinger, A. G. (2020) · Peptide Science · doi:10.1002/pep2.24171 · Cited by 83
Li, X., Zhu, Q., Shi, X., Cheng, Y., Li, X., Xu, H., Duan, X., Hsieh‐Wilson, L. C., Chu, J., Pelletier, J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1813026116 · Cited by 82
“Formation of eIF4F, one of the rate-limiting steps during initiation, is aberrantly regulated during cellular transformation and tumorigenesis (3, 9).”
Self-citationVaklavas, C., Blume, S. W., & Grizzle, W. E. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00158 · Cited by 73
“Other transcription factors can also modulate eIF4F assembly and activity (66).”
BackgroundInfluentialCatalysis-Based Total Syntheses of Pateamine A and DMDA-Pat A
Zhuo, C., & Fürstner, A. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b05094 · Cited by 82
Control of the eIF4E activity: structural insights and pharmacological implications
Romagnoli, A., D’Agostino, M., Ardiccioni, C., Maracci, C., Motta, S., Teana, A. L., & Marino, D. D. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03938-z · Cited by 81
Lymphangioleiomyomatosis: A Monogenic Model of Malignancy
Krymskaya, V. P., & McCormack, F. X. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-050715-104245 · Cited by 81
Human eIF3: from ‘blobology’ to biological insight
Cate, J. H. D. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0176 · Cited by 79
Polysome-profiling in small tissue samples
Liang, S., Bellato, H. M., Lorent, J., Lupinacci, F. C. S., Oertlin, C., van Hoef, V., Andrade, V. P., Roffé, M., Masvidal, L., Hajj, G. N. M., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx940 · Cited by 78
“Moreover dysregulation of translation is associated with pathologies as diverse as fibrosis (12), cancer (13) and neurodegenerative disease (14– 17).”
BackgroundRole of Eukaryotic Initiation Factors during Cellular Stress and Cancer Progression
Sharma, D. K., Bressler, K. R., Patel, H., Balasingam, N., & Thakor, N. (2016) · Journal of Nucleic Acids · doi:10.1155/2016/8235121 · Cited by 79
Sánchez‐Martínez, R., Cruz-Gil, S., García-Álvarez, M. S., Reglero, G., & de Molina, A. R. (2017) · Scientific Reports · doi:10.1038/s41598-017-11612-3 · Cited by 78
Khan, S., Zakariah, M., Rolfo, C. D., Lembrechts, R., & Palaniappan, S. (2016) · Oncotarget · doi:10.18632/oncotarget.8306 · Cited by 77
Pellegrino, S., Meyer, M., Zorbas, C., Bouchta, S. A., Saraf, K., Pelly, S. C., Yusupova, G. Z., Evidente, A., Mathieu, V., Kornienko, A., et al. (2018) · Structure · doi:10.1016/j.str.2018.01.009 · Cited by 77
“The high production rate of proteins in cancer cells, driven by its dysregulated control, makes the inhibition of the eukaryotic protein synthesis an attractive target for the development of anticancer agents (Bhat et al., 2015; Pelletier and Peltz, 2007).”
BackgroundTranslational control and the cancer cell response to stress
Robichaud, N., & Sonenberg, N. (2017) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.05.007 · Cited by 70
“Despite the importance of translation in cancer, its targeting in cancer patients has not been achieved, notwithstanding some notable benefits of rapamycin analogs [4].”
InfluentialSelf-citationEukaryotic translation initiation factors and cancer
Ali, M. U., Rahman, M. S. U., Jia, Z., & Jiang, C. (2017) · Tumor Biology · doi:10.1177/1010428317709805 · Cited by 76
Regulation of gene expression via translational buffering
Kusnadi, E. P., Timpone, C., Topisirović, I., Larsson, O. S., & Furic, L. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.119140 · Cited by 76
Brina, D., Ponzoni, A. A., Troiani, M., Calì, B., Pasquini, E., Attanasio, G., Mosole, S., Mirenda, M., D’Ambrosio, M., Colucci, M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00594-z · Cited by 75
Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors
Chu, J., Zhang, W., Cencic, R., Devine, W. G., Beglov, D., Henkel, T., Brown, L. E., Vajda, S., Porco, J. A., & Pelletier, J. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.08.008 · Cited by 74
“Rocaglates are a class of translation inhibitors that possess potent cytotoxic activity against tumor cells (Bhat et al., 2015).”
Self-citationmTOR-sensitive translation: Cleared fog reveals more trees
Masvidal, L., Hulea, L., Furic, L., Topisirovic, I., & Larsson, O. (2017) · RNA Biology · doi:10.1080/15476286.2017.1290041 · Cited by 73
“are required to mount an optimal response to a variety of stimuli; and when dysregulated can lead to a wide array of pathologies.(13) Thus, deciphering mechanisms by which translation efficiencies of individual mRNAs are reprogrammed in response to stimuli and/or in normal vs.”
BackgroundSelf-citationRNA binding proteins (RBPs) and their role in DNA damage and radiation response in cancer
Mehta, M., Raguraman, R., Ramesh, R., & Munshi, A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114569 · Cited by 74
Manier, S., Huynh, D., Shen, Y. J., Zhou, J., Yusufzai, T., Salem, K. Z., Ebright, R. Y., Shi, J., Park, J., Glavey, S. V., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2668 · Cited by 70
eIF3a: A new anticancer drug target in the eIF family
Yin, J., Zhang, J., Zhang, W., Zhou, H.-H., & Liu, Z. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.055 · Cited by 74
“Inhibitors of eIF4Aare identifiedbyhigh-throughput screening,wherebyphase II clinical trials of eIF4E antisense oligonucleotides in combination with chemotherapy are conducted [84,85].”
BackgroundPérez‐Guijarro, E., Karras, P., Cifdaloz, M., Martínez-Herranz, R., Cañón, E., Graña‐Castro, O., Horcajada‐Reales, C., Alonso‐Curbelo, D., Calvo, T. G., Goméz-López, G., et al. (2016) · Nature Communications · doi:10.1038/ncomms13418 · Cited by 73
The crosstalk between metabolism and translation
Biffo, S., Ruggero, D., & Santoro, M. M. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.07.022 · Cited by 72
Abdelfattah, N., Rajamanickam, S., Subbarayalu, P., Timilsina, S., Yadav, P., Onyeagucha, B. C., Garcia, M., Vadlamudi, R. K., Chen, Y., Brenner, A. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06808-8 · Cited by 71
Antiaging Strategies and Remedies: A Landscape of Research Progress and Promise
Tenchov, R., Sasso, J. M., Wang, X., & Zhou, Q. A. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00532 · Cited by 72
Hippuristanol - A potent steroid inhibitor of eukaryotic initiation factor 4A
Cencic, R., & Pelletier, J. (2016) · Translation · doi:10.1080/21690731.2015.1137381 · Cited by 62
Self-citationSantag, S., Siegel, F., Wengner, A. M., Lange, C., Bömer, U., Eis, K., Pühler, F., Lienau, P., Bergemann, L., Michels, M., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.12.029 · Cited by 71
FKBP10 Regulates Protein Translation to Sustain Lung Cancer Growth
Ramadori, G., Ioris, R. M., Villányi, Z., Firnkes, R., Panasenko, O. O., Allen, G. E., Konstantinidou, G., Aras, E., Brénachot, X., Biscotti, T., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.082 · Cited by 70
“, PTEN and P53) lead to dysregulation of the protein synthesis rate (Bhat et al., 2015).”
Precision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics
Advani, D., Sharma, S., Kumari, S., Ambasta, R. K., & Kumar, P. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210308101029 · Cited by 70
The Role of WNT Pathway Mutations in Cancer Development and an Overview of Therapeutic Options
Groenewald, W., Lund, A. H., & Gay, D. M. (2023) · Cells · doi:10.3390/cells12070990 · Cited by 70
“Deregulated translation is a hallmark of many cancers [87]; however, it could be especially relevant in certain WNT-driven cancers, particularly colorectal cancer [88].”
BackgroundYakhni, M., Briat, A., Guerrab, A. E., Furtado, L., Kwiatkowski, F., Miot-Noirault, E., Cachin, F., Penault-Llorca, F. M., & Radosevic‐Robin, N. (2019) · PubMed Central · Cited by 69
General and Target-Specific DExD/H RNA Helicases in Eukaryotic Translation Initiation
Shen, L. L., & Pelletier, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124402 · Cited by 69
Self-citationYi, W., Gupta, S. K., Ricker, E., Manni, M., Jessberger, R., Chinenov, Y. V., Molina, H., & Pernis, A. B. (2017) · Nature Communications · doi:10.1038/s41467-017-00348-3 · Cited by 67
Ravi, V., Jain, A., Khan, D., Ahamed, F., Mishra, S., Giri, M., Inbaraj, M., Krishna, S., Sarikhani, M., Maity, S., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz648 · Cited by 67
“Increased protein synthesis is crucial for survival, proliferation, progression and transformation of cancer cells (53).”
BackgroundWild, K., Aleksić, M., Lapouge, K., Juaire, K. D., Flemming, D., Pfeffer, S., & Sinning, I. (2020) · Nature Communications · doi:10.1038/s41467-020-14603-7 · Cited by 63
Chen, Z.-H., Qi, J.-J., Wu, Q.-N., Lu, J.-H., Liu, Z.-X., Wang, Y., Hu, P.-S., Li, T., Lin, J.-F., Wu, X.-Y., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1178-z · Cited by 63
Oncogene-dependent sloppiness in mRNA translation
Champagne, J., Pataskar, A., Blommaert, N., Nagel, R., Wernaart, D., Ramalho, S., Kenski, J. C. N., Bleijerveld, O. B., Zaal, E. A., Berkers, C. R., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.09.002 · Cited by 66
Han, X., Zhao, R., Meng, W., & Liao, Y. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.04.009 · Cited by 66
“Because the translation mechanism integrates almost all oncogenic signals and has extensive and crucial effects on oncogene protein expression, targeting the components of this machinery is promising for overcoming disease heterogeneity [5].”
BackgroundAmicoumacin A induces cancer cell death by targeting the eukaryotic ribosome
Prokhorova, I. V., Akulich, K. A., Makeeva, D. S., Osterman, I. А., Skvortsov, D. A., Владимирович, С. П., Dontsova, O. А., Yusupova, G. Z., Yusupov, M., & Dmitriev, S. E. (2016) · Scientific Reports · doi:10.1038/srep27720 · Cited by 66
Shirokikh, N. E., Archer, S. K., Beilharz, T. H., Powell, D., & Preiß, T. (2017) · Nature Protocols · doi:10.1038/nprot.2016.189 · Cited by 65
Tetracyclines Modify Translation By Targeting Key Human rRNA Substructures
Mortison, J. D., Schenone, M., Myers, J. A., Zhang, Z., Chen, L., Ciarlo, C., Comer, E. J., Natchiar, S. K., Carr, S. A., Klaholz, B. P., et al. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.09.010 · Cited by 64
Zhao, J., Zou, J., Jiao, W., Lin, L., Wang, J., & Lin, Z. (2022) · Scientific Reports · doi:10.1038/s41598-022-22879-6 · Cited by 63
Multiplexed Thiol Reactivity Profiling for Target Discovery of Electrophilic Natural Products
Tian, C., Sun, R., Liu, K., Fu, L., Liu, X., Zhou, W., Yang, Y., & Yang, J. H. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.022 · Cited by 63
40 Years of Research Put p53 in Translation
Marcel, V., Long, F. N. V., & Diaz, J. (2018) · Cancers · doi:10.3390/cancers10050152 · Cited by 62
“Interestingly, several studies showed that targeting of the cap-recognition complex with direct inhibitors of eIFs or inhibitors of upstream signaling pathways decreases tumor growth and overall exhibit anti-cancer activity [42].”
BackgroundLin, S., & Kuang, M. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00884-y · Cited by 62
Rocaglamide and silvestrol: a long story from anti-tumor to anti-coronavirus compounds
Schulz, G., Victoria, C., Kirschning, A., & Steinmann, E. (2020) · Natural Product Reports · doi:10.1039/d0np00024h · Cited by 62
Geter, P. A., Ernlund, A. W., Bakogianni, S., Alard, A., Arju, R., Giashuddin, S. M., Gadi, A., Bromberg, J., & Schneider, R. J. (2017) · Genes & Development · doi:10.1101/gad.305631.117 · Cited by 62
“The nature of the increased requirement for eIF4Ewithmalignancy is thought to involve selective mRNA translation, but the mechanism is complex and remains only partially understood (Waskiewicz et al. 1999; Topisirovic and Sonenberg 2011a; Bhat et al. 2015).”
Translational dysregulation in cancer: eIF4A isoforms and sequence determinants of eIF4A dependence
Raza, F., Waldron, J. A., & Quesne, J. L. (2015) · Biochemical Society Transactions · doi:10.1042/bst20150163 · Cited by 61
Shen, L. L., & Pelletier, J. (2019) · Natural Product Reports · doi:10.1039/c9np00052f · Cited by 61
Self-citationExpression and Functional Roles of Eukaryotic Initiation Factor 4A Family Proteins in Human Cancers
Xue, C., Gu, X., Li, G., Bao, Z., & Li, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.711965 · Cited by 60
Carvalho, A., Chu, J., Meinguet, C., Robert Kiss, A., Vandenbussche, G., Masereel, B., Wouters, J., Kornienko, A., Pelletier, J., & Mathieu, V. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.03.034 · Cited by 60
“Similarly, eIF3e and eIF3h have been both reported to be dysregulated in cancer (Bhat et al., 2015).”
InfluentialSelf-citationSathe, A., Chalaud, G., Oppolzer, I. A., Wong, K. Y., von Busch, M., Schmid, S. C., Tong, Z., Retz, M. M., Gschwend, J. E., Schulz, W. A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190854 · Cited by 60
“Understanding the regulation of 4E-BP1 phosphorylation is imperative since its inhibition is required to mediate an effective reduction in cell growth and proliferation [35].”
BackgroundJadhav, K., Abhang, A., Kole, E. B., Gadade, D. D., Dusane, A., Iyer, A., Sharma, A., Rout, S. K., Gholap, A. D., Naik, J., et al. (2025) · Bioengineering · doi:10.3390/bioengineering12050481 · Cited by 59
“These include the dysregulation of translational machinery [72], alterations in epigenetic regulatory mechanisms [73], and the overproduction of enzymes crucial for their survival and evasion of the body’s natural defense mechanisms against uncontrolled proliferation [74].”
Kumar, K., Chow, C. R., Ebine, K., Arslan, A. D., Kwok, B., Bentrem, D. J., Eckerdt, F., Platanias, L. C., & Munshi, H. G. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0285 · Cited by 59
“Dysregulation of mRNA translation contributes to treatment resistance and tumor progression (17, 18).”
BackgroundLawford‐Smith, H. (2015) · Journal of Social Ontology · doi:10.1515/jso-2015-0008 · Cited by 59
Wang, H., Lu, J. L., Edmunds, L. R., Kulkarni, S., Dolezal, J. M., Tao, J., Ranganathan, S., Jackson, L. E., Fromherz, M., Beer–Stolz, D., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.754218 · Cited by 58
“Ribosomal biogenesis and protein translation, both of which are highly energy-consuming processes, increase as a consequence of Myc overexpression and are rate-limiting determinants of many tumor types (40, 41).”
BackgroundMetabolic regulation of prostate cancer heterogeneity and plasticity
Peitzsch, C., Gorodetska, I., Klusa, D., Shi, Q., Alves, T. C., Pantel, K., & Dubrovska, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.002 · Cited by 58
Transcriptional profiling analysis and functional prediction of long noncoding RNAs in cancer
Yuan, J., Yue, H., Zhang, M., Luo, J., Liu, L., Wu, W., Xiao, T., Chen, X., Chen, X., Zhang, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6993 · Cited by 57
“Although such lncRNAs might explain complex and heterogeneous nature of different cancer types [23], it would be more desirable to discover PCGs or lncRNAs as indicators in various types of cancer.”
BackgroundTranslation control during prolonged mTORC1 inhibition mediated by 4E-BP3
Tsukumo, Y., Alain, T., Fonseca, B. D., Nadon, R., & Sonenberg, N. (2016) · Nature Communications · doi:10.1038/ncomms11776 · Cited by 57
Self-citationPeptide Channeling: The Key to MHC Class I Immunosurveillance?
Yewdell, J. W., Dersh, D., & Fåhræus, R. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.09.004 · Cited by 57
Translation initiation in cancer at a glance
Smith, R. C. L., Kanellos, G., Vlahov, N., Alexandrou, C., Willis, A. E., Knight, J. R. P., & Sansom, O. J. (2021) · Journal of Cell Science · doi:10.1242/jcs.248476 · Cited by 57
Bush, M. S., Crowe, N., Zheng, T., & Doonan, J. H. (2015) · The Plant Journal · doi:10.1111/tpj.13062 · Cited by 56
“Because of the recent identification of mammalian eIF4A as an oncogene drug target (Bhat et al., 2015), the extent to which these RNA helicases play a role in differential translation is a particularly pertinent question that is receiving much attention.”
BackgroundNatural scaffolds in anticancer therapy and precision medicine
Mazumder, A., Cerella, C., & Diederich, M. F. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.04.009 · Cited by 56
Waldron, J. A., Tack, D. C., Ritchey, L. E., Gillen, S. L., Wilczynska, A., Turro, E., Bevilacqua, P. C., Assmann, S. M., Bushell, M., & Quesne, J. P. C. L. (2019) · Genome biology · doi:10.1186/s13059-019-1901-2 · Cited by 56
Müller, C., Obermann, W., Schulte, F. W., Lange‐Grünweller, K., Oestereich, L., Elgner, F., Glitscher, M., Hildt, E., Singh, K., Wendel, H., et al. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104706 · Cited by 56
“6B) indicate that an unstructured sequence of sufficient length, e.g. the (AC)15 sequence does not require the helicase activity of eIF4A to allow 43S PIC binding as a prerequisite for translation initiation, whereas a stable hairpin structure likely prevents 43S PIC binding and thus needs to be unwound.”
BackgroundeIF4AII is dispensable for miRNA-mediated gene silencing
Galicia-Vázquez, G., Chu, J., & Pelletier, J. (2015) · RNA · doi:10.1261/rna.052225.115 · Cited by 48
“MicroRNAs (miRNAs) are short noncoding RNAs that regulate gene expression through partial complementary base-pairing to the 3′ untranslated region (UTR) of target mRNAs.”
BackgroundSelf-citationHavrylyuk, D., Howerton, B. S., Nease, L. A., Parkin, S., Heidary, D. K., & Glazer, E. C. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.044 · Cited by 55
Targeting of the Eukaryotic Translation Initiation Factor 4A Against Breast Cancer Stemness
Sridharan, S., Robeson, M., Tukaramrao, D. B., Howard, C. M., Subramaniyan, B., Tilley, A. M. C., Tiwari, A. K., & Raman, D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01311 · Cited by 55
Pharmacological Manipulation of Translation as a Therapeutic Target for Chronic Pain
Yousuf, M. S., Shiers, S. I., Sahn, J. J., & Price, T. J. (2020) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000030 · Cited by 55
“Translation is a tightly regulated process that is increasing viewed as a potential target for therapeutic development in a variety of disease states (Sonenberg and Hinnebusch, 2009; Bhat et al., 2015; Khoutorsky and Price, 2018).”
BackgroundThe eIF2-alpha kinase HRI: a potential target beyond the red blood cell
Burwick, N. R., & Aktas, B. H. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1397133 · Cited by 54
Cellular control of protein levels: A systems biology perspective
Munro, V., Kelly, V. C., Messner, C. B., & Kustatscher, G. (2023) · PROTEOMICS · doi:10.1002/pmic.202200220 · Cited by 54
“For example, translation and degradation inhibitors show great promise for the treatment of heterogeneous cancers, because multiple pathways that are activated in cancer ultimately converge on these processes [143, 144].”
BackgroundDysregulation of mRNA translation and energy metabolism in cancer
Leibovitch, M., & Topisirović, I. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.11.001 · Cited by 53
“The dysregulation of mRNA translation is a prominent characteristic of cancer cells (Bhat et al., 2015; Pelletier et al., 2015).”
BackgroundKey contribution of eIF4H-mediated translational control in tumor promotion
Vaysse, C., Philippe, C., Martineau, Y., Quelen, C., Hiéblot, C., Renaud, C., Nicaise, Y., Desquesnes, A., Pannese, M., Filleron, T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5442 · Cited by 51
“It has now become clear that genetic and epigenetic alterations are only the first layer of genetic reprogramming associated with tumor progression and that post-transcriptional regulation, including the control of mRNA translation, plays an important role in malignant transformation [40].”
BackgroundBell, J. B., Eckerdt, F., Alley, K., Magnusson, L. P., Hussain, H., Bi, Y., Arslan, A. D., Clymer, J. R., Alvarez, A. A., Goldman, S., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0172 · Cited by 51
Inhibition of Eukaryotic Translation by the Antitumor Natural Product Agelastatin A
McClary, B., Zinshteyn, B., Meyer, M., Jouanneau, M., Pellegrino, S., Yusupova, G. Z., Schuller, A. P., Reyes, J. C. P., Lu, J., Guo, Z., et al. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.04.006 · Cited by 51
“Due to their higher proliferation rate and consequently higher demand for newly synthesized proteins, cancer cells in general appear more vulnerable to inhibitors of translation, creating a therapeutic window, albeit a narrow one, for those inhibitors as potential anticancer drugs (Bhat et al., 2015).”
BackgroundInfluentialZeng, H., Yu, M., Tan, H., Li, Y., Su, W., Shi, H., Dhungana, Y., Guy, C. S., Neale, G. A. M., Cloer, C. M., et al. (2018) · Science Advances · doi:10.1126/sciadv.aar5701 · Cited by 51
The TLK1-Nek1 axis promotes prostate cancer progression
Singh, V., Jaiswal, P. K., Ghosh, I., Koul, H. K., Yu, X., & Benedetti, A. D. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.041 · Cited by 51
Thompson, P. A., Eam, B., Young, N. P., Fish, S., Chen, J., Barrera, M., Howard, H., Sung, E., Parra, A., Staunton, J., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0973 · Cited by 50
“eIF4A or the loss of PDCD4 expression has been associated with poor prognosis in multiple disease indications (2, 12).”
BackgroundCirzi, C., Dyckow, J., Legrand, C., Schott, J., Guo, W., Pérez-Hernández, D., Hisaoka, M., Parlato, R., Pitzer, C., van der Hoeven, F., et al. (2023) · The EMBO Journal · doi:10.15252/embj.2022112507 · Cited by 52
“In agreement with our previous observations in HeLa cells (Tuorto et al , 2018), eIF2 signaling, a critical stress-induced regulator of eukaryotic translation (Bhat et al , 2015), was deregulated both in the translatome of the Q1 hippocampi and by Western blot (Figs 6C and 7A, and EV5B).”
ResultEngineered mRNA Delivery Systems for Biomedical Applications
Wang, J., Zhu, H., Gan, J., Liang, G., Li, L., & Zhao, Y. (2024) · Advanced Materials · doi:10.1002/adma.202308029 · Cited by 50
Zhuo, C., & Fürstner, A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201602125 · Cited by 50
Along the Central Dogma—Controlling Gene Expression with Small Molecules
Schneider‐Poetsch, T., & Yoshida, M. (2018) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-033923 · Cited by 50
Peters, T. L., Tillotson, J., Yeomans, A., Wilmore, S., Lemm, E. A., Jiménez-Romero, C., Amador, L. A., Li, L., Amin, A. D., Pongtornpipat, P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3645 · Cited by 50
“Drugs targeting signaling molecules, typically kinases, have made substantial contributions to cancer therapeutic options, but short-lived responses in most clinical scenarios illustrate the ease with which messenger molecules may be bypassed by parallel or redundant signals (1, 2, 16).”
BackgroundJaiswal, P. K., Koul, S., Palanisamy, N., & Koul, H. K. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0947-2 · Cited by 50
“The activity of EIF4F is regulated by two major signaling networks PI3K/mTOR and RAS/MAPK (mitogen-activated protein kinase) pathway [12, 13].”
BackgroundThe MNK1/2–eIF4E Axis Supports Immune Suppression and Metastasis in Postpartum Breast Cancer
Guo, Q., Bartish, M., Gonçalves, C., Huang, F., Smith-Voudouris, J., Krisna, S. S., Preston, S. E. J., Émond, A., Li, V. Z., Duerr, C. U., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3143 · Cited by 50
Bharathkumar, H., Mohan, C. D., Rangappa, S., Kang, T., Keerthy, H. K., Fuchs, J. E., Kwon, N. H., Bender, A., Kim, S., Basappa, B., et al. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob00791g · Cited by 49
Synthesis of Aza‐Rocaglates via ESIPT‐Mediated (3+2) Photocycloaddition
Wang, W., Cencic, R., Whitesell, L. J., Pelletier, J., & Porco, J. A. J. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201602953 · Cited by 49
Self-citationBrumwell, A., Fell, L., Obress, L., & Uniacke, J. (2020) · RNA · doi:10.1261/rna.070318.119 · Cited by 49
“In support of ribosome heterogeneity in cancer, translational control in general has been extensively shown to be deregulated in cancer and is currently a major target of chemotherapeutics (Bhat et al. 2015).”
BackgroundLicochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells
Yuan, L., Jiang, X., Xu, Y., Huang, M., Chen, Y., Yu, W., Su, M., Ye, Z.-H., Chen, X., Wang, Y., et al. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153394 · Cited by 50
mTOR-dependent translation amplifies microglia priming in aging mice
Keane, L., Antignano, I., Riechers, S.-P., Zollinger, R., Dumas, A. A., Offermann, N., Bernis, M. E., Russ, J., Graelmann, F., McCormick, P. N., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci155208 · Cited by 36
Yewdell, J. W., & Hollý, J. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.05.009 · Cited by 48
Kong, S., Kim, W., Lee, H., & Kim, H. (2017) · The FASEB Journal · doi:10.1096/fj.201700780r · Cited by 48
“Recently published research has revealed that eIF4E dysregulation is associated with carcinogenesis, and the inhibition of protein translation (22).”
Background
Metadata
- Authors
- Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I.
- Affiliations
- McGill University Health Centre (CA)
- McGill University (CA)
- Jewish General Hospital (CA)
- Corresponding author
- Sonenberg, Nahum
- Pelletier, Jerry
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-03-06
- Volume
- 14
- Issue
- 4
- Pages
- 261-278
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2040885133
- Cited by
- 799
- References
- 291
- Citations by year
- 2026: 40 · 2025: 44 · 2024: 69 · 2023: 77 · 2022: 58 · 2021: 75 · 2020: 92 · 2019: 70 · 2018: 89 · 2017: 99 · 2016: 65 · 2015: 19
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- eScholarship@McGill (McGill) (submittedVersion)
- Funders
- Howard Hughes Medical Institute (55007654)
- Canadian Institutes of Health Research (MOP115-195, MOP#115126, 106530_1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Keywords
- mRNA translation, translation machinery, cancer, eIF4F, translation initiation, oncogenes, tumour suppressor, anticancer agents, intra-tumour heterogeneity, drug development
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, RNA, Messenger, Protein Biosynthesis, Gene Expression Regulation, Neoplastic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.